Daniel Ye

Daniel Ye

Auto-generated profile, based on publicly available information

Daniel Ye

Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (NINDS/NIH), Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2017 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
JBJoshua Bernstock
Joshua Bernstock
LPLuca Peruzzotti-Jametti
Luca Peruzzotti-Jametti
DYDaniel Ye
Daniel Ye
FGFlorian A Gessler
Florian A Gessler
DMDragan Maric
Dragan Maric
JHJohn M Hallenbeck
John M Hallenbeck
Ischemic stroke continues to be a leading cause of morbidity and mortality throughout the world. To protect and/or repair the ischemic brain, a multitiered approach may be centered on neural stem cell (NSC) transplantation. Transplanted NSCs exert beneficial effects not only via structural replacement, but also via immunomodulatory and/or neurotrophic actions. Unfortunately, the clinical translation of such promising therapies remains elusive, in part due to their limited persistence/survivability within the hostile ischemic microenvironment. Herein, we discuss current approaches for the development of NSCs more amenable to survival within the ischemic brain as a tool for future cellular therapies in stroke.

1 April 2019 in EBioMedicine
Verified
Journal Article
Open access
JBJoshua Bernstock
Joshua Bernstock
LPLuca Peruzzotti-Jametti
Luca Peruzzotti-Jametti
TLTommaso Leonardi
Tommaso Leonardi
Nunzio VicarioNunzio Vicario
Nunzio Vicario
DYDaniel Ye
Daniel Ye
Stefano PluchinoStefano Pluchino
Stefano Pluchino
Neural stem cell (NSC)-based therapies hold great promise for treating diseases of the central nervous system (CNS). However, several fundamental problems still need to be overcome to fully exploit the clinical potential of NSC therapeutics. Chief among them is the limited survival of NSC grafts within hostile microenvironments. Herein, we sought to engineer NSCs in an effort to increase graft survival within ischemic brain lesions via upregulation of global SUMOylation, a post-translational modification critically involved in mediating tolerance to ischemia/reperfusion. NSCs overexpressing the SUMO E2-conjugase Ubc9 displayed resistance to oxygen-glucose-deprivation/restoration of oxygen/glucose (OGD/ROG) and enhanced neuronal differentiation in vitro, as well as increased survival and neuronal differentiation when transplanted in mice with transient middle cerebral artery occlusion in vivo. Our work highlights a critical role for SUMOylation in NSC biology and identifies a biological pathway that can be targeted to increase the effectiveness of exogenous stem cell medicines in ischemic stroke. FUND: Intramural Research Program of the NINDS/NIH, the Italian Multiple Sclerosis Foundation (FISM), the Bascule Charitable Trust, NIH-IRTA-OxCam and Wellcome Trust Research Training Fellowships.

17 November 2017 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
JBJoshua Bernstock
Joshua Bernstock
Wei YangWei Yang
Wei Yang
DYDaniel G Ye
Daniel G Ye
YSYuntian Shen
Yuntian Shen
SPStefano Pluchino
Stefano Pluchino
WPWulf Paschen
Wulf Paschen
Post-translational protein modification by small ubiquitin-like modifier (SUMO) regulates a myriad of homeostatic and stress responses. The SUMOylation pathway has been extensively studied in brain ischemia. Convincing evidence is now at hand to support the notion that a major increase in levels of SUMOylated proteins is capable of inducing tolerance to ischemic stress. Therefore, the SUMOylation pathway has emerged as a promising therapeutic target for neuroprotection in the face of brain ischemia. Despite this, it is prudent to acknowledge that there are many key questions still to be addressed in brain ischemia related to SUMOylation. Accordingly, herein, we provide a critical review of literature within the field to summarize current knowledge and in so doing highlight pertinent translational implications of the SUMOylation pathway in brain ischemia.

7 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JBJoshua Bernstock
Joshua Bernstock
DYDaniel Ye
Daniel Ye
FGFlorian Gessler
Florian Gessler
YLYang-Ja Lee
Yang-Ja Lee
LPLuca Peruzzotti-Jametti
Luca Peruzzotti-Jametti
JHJohn M. Hallenbeck
John M. Hallenbeck
Protein SUMOylation is a dynamic post-translational modification shown to be involved in a diverse set of physiologic processes throughout the cell. SUMOylation has also been shown to play a role in the pathobiology of myriad cancers, one of which is glioblastoma multiforme (GBM). As such, the clinical significance and therapeutic utility offered via the selective control of global SUMOylation is readily apparent. There are, however, relatively few known/effective inhibitors of global SUMO-conjugation. Herein we describe the identification of topotecan as a novel inhibitor of global SUMOylation. We also provide evidence that inhibition of SUMOylation by topotecan is associated with reduced levels of CDK6 and HIF-1α, as well as pronounced changes in cell cycle progression and cellular metabolism, thereby highlighting its putative role as an adjuvant therapy in defined GBM patient populations.

3 January 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JBJoshua Bernstock
Joshua Bernstock
DYDaniel Ye
Daniel Ye
JSJayden A. Smith
Jayden A. Smith
YLYang‐Ja Lee
Yang‐Ja Lee
FGFlorian A. Gessler
Florian A. Gessler
Wei YangWei Yang
Wei Yang
The development of novel neuroprotective treatments for acute stroke has been fraught with failures, which supports the view of ischemic brain damage as a highly complex multifactorial process. Post‐translational modifications such as small ubiquitin‐like modifier (SUMO)ylation have emerged as critical molecular regulatory mechanisms in states of both homeostasis and ischemic stress, as evidenced by our previous work. Accordingly, the clinical significance of the selective control of the global SUMOylation process has become apparent in studies of ischemic pathobiology and pathophysiology. Herein, we describe a process capable of identifying and characterizing small molecules with the potential of targeting the SUMO system through inhibition of SUMO deconjugation in an effort to develop novel stroke therapies.—Bernstock, J. D., Ye, D., Smith, J. A., Lee, Y.‐J., Gessler, F. A., Yasgar, A., Kouznetsova, J., Jadhav, A., Wang, Z., Pluchino, S., Zheng, W., Simeonov, A., Hallenbeck, J. M., Yang, W. Quantitative high‐throughput screening identifies cytoprotective molecules that enhance SUMO‐conjugation via the inhibition of SUMO‐specific protease (SENP)2. FASEB J. 32, 1677‐1691 (2018). www.fasebj.org

1 August 2016 in Early Human Development
Verified
Journal Article
Closed access
ARAndrew Romaine
Andrew Romaine
DYDaniel Ye
Daniel Ye
ZAZachary Ao
Zachary Ao
FFFrancia Fang
Francia Fang
OJOctavious Johnson
Octavious Johnson
CHChristoph P. Hornik
Christoph P. Hornik